Instruments to measure sexual dysfunction in community and psychiatric populations

Rizvi, Sakina J.; Yeung, Niette W.; Kennedy, Sidney H.

doi:10.1016/j.jpsychores.2010.05.009

Cited by 37 publications

(29 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The fewer patients complain about symptoms, the higher the risk of sexual dysfunction. These findings are consistent with those of studies by Bonierbale et al 21 and Rizvi et al 22 Bonierbale et al 21 showed that among 4557 patients with episodes of major depression without previous sexual dysfunction problems, merely 35.0% stated sexual dysfunction, while on being asked by the clinician and using the ASEX questionnaire, it reached 69.0%. This value was 71 and 65.0% in patients treated with antidepressants and those who were not treated, respectively.…”

supporting

confidence: 91%

“…On reviewing the studies conducted between 1970 and 2009, Rizvi et al 22 state that more than 40.0% of women and 30.0% of men in general population suffer from sexual dysfunction; the disorder was twice common in patients with major depressive disorder, and with treatment of depression, sexual dysfunction reaches 30-50% while less than 20.0% of the patients state this problem.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Investigation of the difference between the expression and presence of sexual symptoms and dysfunction in depressed women treated with fluoxetine

Fakhari¹,

Farahbakhsh²,

fakhri³

et al. 2015

J anal res clin med

View full text Add to dashboard Cite

Sexual function is affected by the interaction of multiple factors including personality factors, biological nature of the individual, and his/her overall sense of self. Proper sexual function is vital for many human relations and provides better physical, psychological, and social feelings. 1 Sexual dysfunction can reduces the quality of life, self-esteem and mood impair relationship with spouse. 2,3 Depression is one of sexual disorders risk factors and in depressed individuals; sexual dysfunction is three times prevalent compared with general population. 4 On the other hand, pharmacotherapy can aggravate sexual dysfunction or precipitate it. 5 Almost any medication, especially psychotropics, affectsThe present study aimed at investigating the difference between the expression and presence of sexual symptoms and dysfunction in depressed women treated with fluoxetine, and the possibility of sexual dysfunction following consumption of fluoxetine.This cross-sectional analytic study was conducted on 44 women candidates for receiving fluoxetine after the diagnosis of depression. Patients' complaints of sexual dysfunction were collected and compared using Arizona Sexual Experiences Scale (ASEX) questionnaire during their first visit and 2 months after receiving fluoxetine. Two-way data were analyzed using chi-square test, and Wilcoxon Signed Ranks test was used to study ordinal variables in SPSS software.This study indicates that there is a significant difference between the final score of the ASEX questionnaire and that of each question before and after the consumption of fluoxetine. Using ASEX scale, it was indicated that 11 (25.0%) and 27 (61.4%) of participants suffered from sexual dysfunction at their first and second visit, respectively, and that there is a correlation between the expression of sexual dysfunction symptoms and sexual dysfunction disorder.Results indicate that consumption of fluoxetine causes sexual dysfunction, and there is a correlation between the expression of sexual dysfunction symptoms and sexual dysfunction disorder. Moreover the fewer participants complain about symptoms, the more the chance of sexual dysfunction.

show abstract

supporting

confidence: 91%

mentioning

confidence: 99%

Investigation of the difference between the expression and presence of sexual symptoms and dysfunction in depressed women treated with fluoxetine

Fakhari¹,

Farahbakhsh²,

fakhri³

et al. 2015

J anal res clin med

View full text Add to dashboard Cite

show abstract

“…[28] The GRISS, a self-reporting questionnaire, was designed to assess the quality of a heterosexual relationship and individual sexual functioning. [29,30] The BMSFI was developed as a validated way to characterize sexual function by clinicians and researchers. [31] Dinçer et al [13] used the BMSFI scale and found that all of its domains, except for the ejaculation domain, were significantly lower in male patients with AS compared with healthy controls.…”

Section: Discussionmentioning

confidence: 99%

Assessment of Sexual Functions in Male Patients with Ankylosing Spondylitis Compared with Healthy Controls

Rezvanı

2013

Turk J Rheumatol

View full text Add to dashboard Cite

Amaç: Bu çalışmada, ankilozan spondilitin (AS), erkek hastalarda seksüel fonksiyon üzerindeki etkisi, araştırıldı, sonuçlar sağlıklı erkek kontrollerle karşılaştırıldı ve hastalık ile ilgili değişkenlerle olan ilişkisi belirlendi. Objectives: This study aims to investigate the impact of ankylosing spondylitis (AS) on sexual functions in male patients, to compare the results with healthy male controls, and to identify the associations with disease-related variables. Hastalar ve yöntemler: Patients and methods:A total of 39 male patients with AS (mean age 38 years; range 27 to 52 years) and 27 healthy male subjects (mean age 30 years; range 23 to 45 years) were included in the study. The Bath Ankylosing Spondylitis Metrology Index (BASMI), the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Short Form 36 (SF-36) and the Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire were used for those with AS, while the International Index of Erectile Function (IIEF) and the Beck Depression Inventory (BDI) were utilized for all the study subjects. Results:The frequency of erectile dysfunction in the male patients with AS and the healthy controls was 43.6% and 51.9%, respectively. No statistically significant differences were found with regard to demographic characteristics, the IIEF, or the BDI scores between the two groups (p>0.05). No significant correlation was found between any domain of the IIEF and the AS indices or laboratory parameters. However, erectile function, overall satisfaction, the total IIEF, and the level of erectile dysfunction were found to be correlated with the BDI. Conclusion:Sexual dysfunction is common in male patients with AS; however, we could not find any statistically significant differences between them and the healthy male controls in terms of sexual functions. Sexual dysfunction in male patients with AS seems to be associated with an unfavorable psychological status.

show abstract

“…The use of validated instruments to assess sexual dysfunction seems to enhance the identification and quantification of these adverse events [97]. These adverse reactions are a major contributor of treatment discontinuation and lack of adherence [98,99].…”

Section: Sexual Dysfunctionmentioning

confidence: 99%

The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature

Carvalho

Sharma²,

Brunoni³

et al. 2016

Psychother Psychosom

452

296

View full text Add to dashboard Cite

Newer generation antidepressant drugs (ADs) are widely used as the first line of treatment for major depressive disorders and are considered to be safer than tricyclic agents. In this critical review, we evaluated the literature on adverse events, tolerability and safety of selective serotonin reuptake inhibitors, serotonin noradrenaline reuptake inhibitors, bupropion, mirtazapine, trazodone, agomelatine, vilazodone, levomilnacipran and vortioxetine. Several side effects are transient and may disappear after a few weeks following treatment initiation, but potentially serious adverse events may persist or ensue later. They encompass gastrointestinal symptoms (nausea, diarrhea, gastric bleeding, dyspepsia), hepatotoxicity, weight gain and metabolic abnormalities, cardiovascular disturbances (heart rate, QT interval prolongation, hypertension, orthostatic hypotension), genitourinary symptoms (urinary retention, incontinence), sexual dysfunction, hyponatremia, osteoporosis and risk of fractures, bleeding, central nervous system disturbances (lowering of seizure threshold, extrapyramidal side effects, cognitive disturbances), sweating, sleep disturbances, affective disturbances (apathy, switches, paradoxical effects), ophthalmic manifestations (glaucoma, cataract) and hyperprolactinemia. At times, such adverse events may persist after drug discontinuation, yielding iatrogenic comorbidity. Other areas of concern involve suicidality, safety in overdose, discontinuation syndromes, risks during pregnancy and breast feeding, as well as risk of malignancies. Thus, the rational selection of ADs should consider the potential benefits and risks, likelihood of responsiveness to the treatment option and vulnerability to adverse events. The findings of this review should alert the physician to carefully review the appropriateness of AD prescription on an individual basis and to consider alternative treatments if available.

show abstract

Instruments to measure sexual dysfunction in community and psychiatric populations

Cited by 37 publications

References 64 publications

Investigation of the difference between the expression and presence of sexual symptoms and dysfunction in depressed women treated with fluoxetine

Investigation of the difference between the expression and presence of sexual symptoms and dysfunction in depressed women treated with fluoxetine

Assessment of Sexual Functions in Male Patients with Ankylosing Spondylitis Compared with Healthy Controls

The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature

Contact Info

Product

Resources

About